RCS - EKF Diagnostics Hldg - Investor Presentation – Revised start time

EKF Diagnostics HoldingsAnnouncement

15/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240315:nRSO9464Ga&default-theme=true

RNS Number : 9464G  EKF Diagnostics Holdings PLC  15 March 2024

 

EKF Diagnostics Holdings plc

("EKF", the "Company", or the "Group")

 

 Investor Presentation - Revised start time

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, announces a revised start time for its investor presentation taking
place on Wednesday 20 March 2024.

 

Julian Baines, Executive Chair, and Stephen Young, Chief Financial Officer,
will be hosting a live online presentation relating to the Company's full year
results via the Investor Meet Company platform at the revised time of 3pm GMT
on Wednesday 20 March 2024. The presentation is open to all existing and
potential shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the
presentation here:
https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor
(https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor)

 

Investors who already follow EKF on the Investor Meet Company platform will
automatically be invited to the event at the new start time.

 

If the new time is no longer convenient, please note that a recording of the
presentation, a PDF of the slides used, and responses to the Q&A session
will be available on the Investor Meet Company platform afterwards.

 

 

 EKF Diagnostics Holdings plc                                www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair / Stephen Young, CFO          Tel: +44 (0)29 2071 0570

 Singer Capital Markets (Nominated Adviser & Joint Broker)                                 Tel: +44 (0)20 7496 3000
 Aubrey Powell / Oliver Platts

 Walbrook PR Limited             Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Charlotte Edgar  Mob: +44 (0)7980 541 893 / +44 (0)7884 664 686

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

·   Point-of-Care analysers in the key areas of Hematology and Diabetes, as
well as Central Laboratory products including clinical chemistry reagents,
analysers and centrifuges

 

·   Life Sciences services provide specialist manufacture of enzymes and
custom products for use in diagnostic, food and industrial applications, as
well as other higher value Contract Manufacturing services

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASFEFWLELSEED